Advanced

Dietary intake of acrylamide and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.

Obón-Santacana, Mireia; Peeters, Petra H; Freisling, Heinz; Dossus, Laure; Clavel-Chapelon, Francoise; Baglietto, Laura; Schock, Helena; Fortner, Renée T; Boeing, Heiner and Tjonneland, Anne, et al. (2015) In Cancer Epidemiology Biomarkers & Prevention 24(1). p.291-297
Abstract
Acrylamide, classified in 1994 by IARC as 'probably carcinogenic' to humans, was discovered in 2002 in some heat-treated, carbohydrate-rich foods. The association between dietary acrylamide intake and epithelial ovarian cancer risk (EOC) has been previously studied in one case-control and three prospective cohort studies which obtained inconsistent results, and could not further examine histological subtypes other than serous EOC. The present study was carried out in the European Prospective Investigation into Cancer and Nutrition (EPIC) sub-cohort of women (n=325,006). Multivariate Cox proportional hazards models were used to assess the association between questionnaire-based acrylamide intake and EOC risk. Acrylamide was energy-adjusted... (More)
Acrylamide, classified in 1994 by IARC as 'probably carcinogenic' to humans, was discovered in 2002 in some heat-treated, carbohydrate-rich foods. The association between dietary acrylamide intake and epithelial ovarian cancer risk (EOC) has been previously studied in one case-control and three prospective cohort studies which obtained inconsistent results, and could not further examine histological subtypes other than serous EOC. The present study was carried out in the European Prospective Investigation into Cancer and Nutrition (EPIC) sub-cohort of women (n=325,006). Multivariate Cox proportional hazards models were used to assess the association between questionnaire-based acrylamide intake and EOC risk. Acrylamide was energy-adjusted using the residual method, and was evaluated both as a continuous variable (per 10µg/day) and in quintiles; when subgroups by histological EOC subtypes were analyzed, acrylamide intake was evaluated in quartiles. During a mean follow-up of 11 years, 1,191 incident EOC cases were diagnosed. At baseline, the median acrylamide intake in EPIC was 21.3 μg/day. No associations, and no evidence for a dose-response were observed between energy-adjusted acrylamide intake and EOC risk (HR10µg/day:1.02, 95%CI:0.96-1.09; HRQ5vsQ1:0.97, 95%CI:0.76-1.23). No differences were seen when invasive EOC subtypes (582 serous, 118 endometrioid, and 79 mucinous tumors) were analyzed separately. This study did not provide evidence that acrylamide intake, based on food intake questionnaires, was associated with risk for EOC in EPIC. Additional studies with more reliable estimates of exposure based on biomarkers may be needed. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Epidemiology Biomarkers & Prevention
volume
24
issue
1
pages
291 - 297
publisher
American Association for Cancer Research
external identifiers
  • pmid:25300475
  • wos:000348030700035
  • scopus:84921024859
ISSN
1538-7755
DOI
10.1158/1055-9965.EPI-14-0636
language
English
LU publication?
yes
id
9691a4d4-e9a5-43c8-a718-0e30893664ea (old id 4737201)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25300475?dopt=Abstract
date added to LUP
2014-11-06 20:16:28
date last changed
2017-11-05 03:19:21
@article{9691a4d4-e9a5-43c8-a718-0e30893664ea,
  abstract     = {Acrylamide, classified in 1994 by IARC as 'probably carcinogenic' to humans, was discovered in 2002 in some heat-treated, carbohydrate-rich foods. The association between dietary acrylamide intake and epithelial ovarian cancer risk (EOC) has been previously studied in one case-control and three prospective cohort studies which obtained inconsistent results, and could not further examine histological subtypes other than serous EOC. The present study was carried out in the European Prospective Investigation into Cancer and Nutrition (EPIC) sub-cohort of women (n=325,006). Multivariate Cox proportional hazards models were used to assess the association between questionnaire-based acrylamide intake and EOC risk. Acrylamide was energy-adjusted using the residual method, and was evaluated both as a continuous variable (per 10µg/day) and in quintiles; when subgroups by histological EOC subtypes were analyzed, acrylamide intake was evaluated in quartiles. During a mean follow-up of 11 years, 1,191 incident EOC cases were diagnosed. At baseline, the median acrylamide intake in EPIC was 21.3 μg/day. No associations, and no evidence for a dose-response were observed between energy-adjusted acrylamide intake and EOC risk (HR10µg/day:1.02, 95%CI:0.96-1.09; HRQ5vsQ1:0.97, 95%CI:0.76-1.23). No differences were seen when invasive EOC subtypes (582 serous, 118 endometrioid, and 79 mucinous tumors) were analyzed separately. This study did not provide evidence that acrylamide intake, based on food intake questionnaires, was associated with risk for EOC in EPIC. Additional studies with more reliable estimates of exposure based on biomarkers may be needed.},
  author       = {Obón-Santacana, Mireia and Peeters, Petra H and Freisling, Heinz and Dossus, Laure and Clavel-Chapelon, Francoise and Baglietto, Laura and Schock, Helena and Fortner, Renée T and Boeing, Heiner and Tjonneland, Anne and Olsen, Anja and Overvad, Kim and Menéndez, Virginia and Sanchez, Maria-Jose and Larranaga, Nerea and Huerta Castaño, José María and Barricarte, Aurelio and Khaw, Kay-Tee and Wareham, Nick and Travis, Ruth C and Merritt, Melissa A and Trichopoulou, Antonia and Trichopoulos, Dimitrios and Orfanos, Philippos and Masala, Giovanna and Sieri, Sabina and Tumino, Rosario and Vineis, Paolo and Mattiello, Amalia and Bueno-de-Mesquita, H Bas and Onland-Moret, N Charlotte and Wirfält, Elisabet and Stocks, Tanja and Idahl, Annika and Lundin, Eva and Skeie, Guri and Gram, Inger T and Weiderpass, Elisabete and Riboli, Elio and Duell, Eric J},
  issn         = {1538-7755},
  language     = {eng},
  number       = {1},
  pages        = {291--297},
  publisher    = {American Association for Cancer Research},
  series       = {Cancer Epidemiology Biomarkers & Prevention},
  title        = {Dietary intake of acrylamide and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.},
  url          = {http://dx.doi.org/10.1158/1055-9965.EPI-14-0636},
  volume       = {24},
  year         = {2015},
}